Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.35 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.35 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11666346 | 0.86 | GAA (0.33) | KCNH3MAPTGAAKDM4ENLRP3 | |
| SCHEMBL8897910 | 0.74 | KCNH3 (0.37) | KCNH3S1PR2LMNASMN1; SMN2NPSR1 | |
| SCHEMBL9385508 | 0.72 | GAA (0.43) | MAPTGAA | |
| Anthracene SCHEMBL28851492 | 0.69 | TLR8 (0.40) | LMNASMN1; SMN2MAPTALDH1A1SOAT1 | |
| Benzodiazepine SCHEMBL8530199 | 0.67 | GAA (0.34) | MAPTNPC1ALDH1A1GAA | |
| SCHEMBL992492 | 0.66 | MAPT (0.36) | SMN1; SMN2MAPTRAB9AGAAKDM4E | |
| SCHEMBL2386480 | 0.66 | MAPT (0.48) | SMN1; SMN2MAPTRAB9AGAAKDM4E | |
| SCHEMBL28900117 | 0.65 | MAPT (0.39) | LMNASMN1; SMN2NPSR1MAPTGAA | |
| SCHEMBL9540304 | 0.64 | S1PR2 (0.37) | KCNH3S1PR2LMNASMN1; SMN2NPSR1 | |
| SCHEMBL1724131 | 0.63 | L3MBTL1 (0.51) | KCNH3S1PR2LMNASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4628084-A | AMIDATION, AMMONIATION, CONDENSATION | MERCK & CO., INC. (US) | 1986-12-09 | — | — | US | claimed |
| EP-1326849-B1 | BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE | MERCK SHARP & DOHME (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-7105509-B2 | Benzodiazepine derivatives as APP modulators | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-6995155-B2 | Benzodiazepine derivatives as inhibitors of gamma secretase | MERCK SHARP & DOHME LIMITED (GB) | 2006-02-07 | — | — | US | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
| US-20040024203-A1 | Benzodiazepine derivatives as inhibitors of gamma secretase | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1326849-A1 | BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE | Merck Sharp & Dohme Limited (GB) | 2003-07-16 | — | — | EP | disclosed |
| EP-1294702-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002030912-A1 | BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE | MERCK SHARP & DOHME LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| WO-2001090084-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
| US-5428157-A | Antiarrhythmia agents | MERCK & CO., INC. (US) | 1995-06-27 | — | — | US | disclosed |
| US-4628084-A | AMIDATION, AMMONIATION, CONDENSATION | MERCK & CO., INC. (US) | 1986-12-09 | — | — | US | disclosed |
| US-4628084-A | AMIDATION, AMMONIATION, CONDENSATION | MERCK & CO., INC. (US) | 1986-12-09 | — | — | US | disclosed |
| US-4628084-A | AMIDATION, AMMONIATION, CONDENSATION | MERCK & CO., INC. (US) | 1986-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | BACE1, PSEN1, APP | KCNH3 1428/4885S1PR2 2936/4885LMNA 1324/4885 |
| US-20040024203-A1 | Benzodiazepine derivatives as inhibitors of gamma secretase | BACE1, BACE2, PSEN1 | KCNH3 1341/4885S1PR2 3685/4885LMNA 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.